Patents by Inventor Michael A. Brehm
Michael A. Brehm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11785923Abstract: The present invention relates generally to genetically modified non-human animals and immunodeficient non-human animals characterized by restored complement-dependent cytotoxicity, as well as methods and compositions for assessment of therapeutic antibodies in the genetically modified immunodeficient non-human animals. In specific aspects, the present invention relates to immunodeficient non-obese diabetic (NOD), A/J, A/He, AKR, DBA/2, NZB/B1N, B10.D2/oSn and other mouse strains genetically modified to restore complement-dependent cytotoxicity which is lacking in the unmodified immunodeficient mice. In further specific aspects, the present invention relates to NOD.Cg-Prkdcscid IL2retmlWjl/SzJ (NSG), NOD.Cg-Rag1tm1Mom Il2rgtmlWjl/SzJ (NRG) and NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac (NOG) mice genetically modified to restore complement-dependent cytotoxicity which is lacking in unmodified NSG, NRG and NOG mice.Type: GrantFiled: May 28, 2020Date of Patent: October 17, 2023Assignees: The Jackson Laboratory, University of MassachusettsInventors: Leonard D. Shultz, Mohit Kumar Verma, Dale L. Greiner, Michael A. Brehm
-
Patent number: 11778994Abstract: A NOD.Cg-PrkdcscidH2rgtm1 Wjl/SzJ.(NOD-scid-IL2r?null, NSG) mouse which is genetically modified such that the en NSG mouse lacks functional major histocompatibility complex I (MHC I) and lacks functional major histocompatibility complex II (MHC II) is provided according to aspects of the present, invention. According to specific aspects the genetically modified NSG mouse, is a NOD.Cg-PrkdcscidH2-K1tml Bpe H2-Ab1eml Mvw H2-D1tml Bpe H2rgtm Wjl/SzJ (NSG-Kb Db)null(IAnull)) mouse, NSG-RIP-DTR (Kb Db)null(IAnull) mouse, or a NOD.Cg-B2mtmlUnePrKdcscidH2dlAb1-E?H2rgtm1 Wjl/SzJ (NSG-B2Mnull(IA IEnull)) mouse. Human, immune cells and/or human: tumor cells are administered to a genetically modified immunodeficient mouse according to aspects described herein and assays of one or more test substances can be performed using the provided mice.Type: GrantFiled: May 14, 2018Date of Patent: October 10, 2023Assignees: The Jackson Laboratory, University of MassachusettsInventors: Michael A. Brehm, Michael V. Wiles, Dale L. Greiner, Leonard D. Shultz
-
Patent number: 11138981Abstract: Systems and methods for detection, classification, and diagnosis of vocal anomalies in vocal streams are disclosed. Discussed are a method for generating a biometric voiceprint for analyzing user vocal streams to detect and classify vocal anomalies and a method for notifying the appropriate party, where the notification is based on the diagnosis reported by the system. Manual classification in the event of automatic classification failure is discussed, where the manual classification data can be used as training data to improve the functionality of the classification model.Type: GrantFiled: August 21, 2019Date of Patent: October 5, 2021Assignee: I2X GMBHInventors: Samuel Brown, Mehak Khajuria, Michael Brehm
-
Publication number: 20210056976Abstract: Systems and methods for detection, classification, and diagnosis of vocal anomalies in vocal streams are disclosed. Discussed are a method for generating a biometric voiceprint for analyzing user vocal streams to detect and classify vocal anomalies and a method for notifying the appropriate party, where the notification is based on the diagnosis reported by the system. Manual classification in the event of automatic classification failure is discussed, where the manual classification data can be used as training data to improve the functionality of the classification model.Type: ApplicationFiled: August 21, 2019Publication date: February 25, 2021Inventors: Samuel Brown, Mehak Khajuria, Michael Brehm
-
Publication number: 20200359609Abstract: The present invention relates generally to genetically modified non-human animals and immunodeficient non-human animals characterized by restored complement-dependent cytotoxicity, as well as methods and compositions for assessment of therapeutic antibodies in the genetically modified immunodeficient non-human animals. In specific aspects, the present invention relates to immunodeficient non-obese diabetic (NOD), A/J, A/He, AKR, DBA/2, NZB/B1N, B10.D2/oSn and other mouse strains genetically modified to restore complement-dependent cytotoxicity which is lacking in the unmodified immunodeficient mice. In further specific aspects, the present invention relates to NOD.Cg-Prkdcscid IL2retmlWjl/SzJ (NSG), NOD.Cg-Rag1tm1Mom Il2rgtmlWjl/SzJ (NRG) and NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac (NOG) mice genetically modified to restore complement-dependent cytotoxicity which is lacking in unmodified NSG, NRG and NOG mice.Type: ApplicationFiled: May 28, 2020Publication date: November 19, 2020Applicants: The Jackson Laboratory, University of MassachusettsInventors: Leonard D. Shultz, Mohit Kumar Verma, Dale L. Greiner, Michael A. Brehm
-
Publication number: 20200236916Abstract: An immunodeficient mouse is provided which is useful as a model of functions and regulation of human natural killer (NK) cells and other interleukin 15 (IL-15)-dependent cell populations and processes in studies of human immunity, cancer, infectious diseases, and other areas. According to specific aspects, an immunodeficient mouse is provided which is genetically modified to express human interleukin 15, wherein the mouse does not have or produce functional mouse natural killer cells, and wherein the mouse is modified to include human natural killer cells. Methods of identifying anti-tumor activity of a test substance using a mouse of the present invention are described along with methods of making the mouse.Type: ApplicationFiled: August 9, 2018Publication date: July 30, 2020Applicants: The Jackson Laboratory, University of Massachusetts Medical SchoolInventors: Leonard D. Shultz, Michael A. Brehm, Dale L. Greiner
-
Patent number: 10701911Abstract: The present invention relates generally to genetically modified non-human animals and immunodeficient non-human animals characterized by restored complement-dependent cytotoxicity, as well as methods and compositions for assessment of therapeutic antibodies in the genetically modified immunodeficient non-human animals. In specific aspects, the present invention relates to immunodeficient non-obese diabetic (NOD), A/J, A/He, AKR, DBA/2, NZB/BIN, B10.D2/oSn and other mouse strains genetically modified to restore complement-dependent cytotoxicity which is lacking in the unmodified immunodeficient mice. In further specific aspects, the present invention relates to NOD.Cg-Prkdcscid IL2rgtm1Wjl/SzJ (NSG), NOD.Cg-Rag1tm1Mom IL2rgtm1Wjl/SzJ (NRG) and NOD.Cg-Prkdcscid IL2rgtm1Sug/JicTAc (NOG) mice genetically modified to restore complement-dependent cytotoxicity which is lacking in unmodified NSG, NRG and NOG mice.Type: GrantFiled: June 16, 2016Date of Patent: July 7, 2020Assignees: The Jackson Laboratory, University of MassachusettsInventors: Leonard D. Shultz, Mohit Kumar Verma, Dale L. Greiner, Michael A. Brehm
-
Patent number: 10678499Abstract: An audio interface device, comprising: an interface unit and a wireless unit, wherein the interface unit is configured to relay a first audio signal transmitted between a microphone and a communication device and a second audio signal transmitted between the communication device and a speaker, and to route first audio data related to the first audio signal and second audio data related to the second audio signal to the wireless unit; and wherein the wireless unit is configured to transmit the first audio data and the second audio data to a remote audio device.Type: GrantFiled: January 30, 2019Date of Patent: June 9, 2020Assignee: i2x GmbHInventors: Claudio Martay, Michael Brehm, Evgenii Khamukhin
-
Publication number: 20200174740Abstract: An audio interface device, comprising: an interface unit and a wireless unit, wherein the interface unit is configured to relay a first audio signal transmitted between a microphone and a communication device and a second audio signal transmitted between the communication device and a speaker, and to route first audio data related to the first audio signal and second audio data related to the second audio signal to the wireless unit; and wherein the wireless unit is configured to transmit the first audio data and the second audio data to a remote audio device.Type: ApplicationFiled: January 30, 2019Publication date: June 4, 2020Applicant: i2x GmbHInventors: Claudio Martay, Michael Brehm, Evgenii Khamukhin
-
Publication number: 20200060245Abstract: A NOD.Cg-PrkdcscidH2rgtm1 Wjl/SzJ.(NOD-scid-IL2r?null, NSG) mouse which is genetically modified such that the en NSG mouse lacks functional major histocompatibility complex I (MHC I) and lacks functional major histocompatibility complex II (MHC II) is provided according to aspects of the present, invention. According to specific aspects the genetically modified NSG mouse, is a NOD.Cg-PrkdcscidH2-K1tml Bpe H2-Ab1eml Mvw H2-D1tml Bpe H2rgtm Wjl/SzJ (NSG-Kb Db)null(IAnull)) mouse, NSG-RIP-DTR (Kb Db)null(IAnull) mouse, or a NOD.Cg-B2mtmlUnePrKdcscidH2dlAb1-E?H2rgtm1 Wjl/SzJ (NSG-B2Mnull(IA IEnull)) mouse. Human, immune cells and/or human: tumor cells are administered to a genetically modified immunodeficient mouse according to aspects described herein and assays of one or more test substances can be performed using the provided mice.Type: ApplicationFiled: May 14, 2018Publication date: February 27, 2020Applicants: The Jackson Laboratory, University of MassachusettsInventors: Michael A. Brehm, Michael V. Wiles, Dale L. Greiner, Leonard D. Shultz
-
Publication number: 20190362737Abstract: A method includes using a computing platform to apply a trained supervised machine learning model to a waveform representation of a person's voice data. The model has been trained to determine a probability of the waveform representation producing a desired outcome. The method further includes using the computing platform to modify a parameter of a phonetic characteristic of the waveform representation to produce a modified waveform representation, and apply the trained model to the modified waveform representation to determine whether the modified waveform representation has a higher probability of producing the desired outcome. The waveform representation having the higher probability is outputted.Type: ApplicationFiled: May 25, 2018Publication date: November 28, 2019Inventors: Christoph Feinauer, Claudio Martay, Michael Brehm
-
Publication number: 20190320633Abstract: A genetically-modified, immunodeficient mouse is provided along with methods of use, wherein the mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, and wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1, wherein the genetically-modified, immunodeficient mouse allows engraftment of human hematopoietic stem cells along with engraftment of human-patient derived tumor xenografts and/or human tumor cell lines to enable in vivo investigation of the interactions between the human immune system and human cancer.Type: ApplicationFiled: November 30, 2017Publication date: October 24, 2019Applicants: The Jackson Laboratory, University of MassachusettsInventors: Leonard D. Shultz, James G. Keck, Dale L. Greiner, Michael A. Brehm
-
Patent number: 10146048Abstract: An optical assembly (1) includes an optical element (2), a mount (3) configured to hold the optical element (2), and a plurality of fastening elements (12) with fastening areas (14) configured to fasten the optical element (2) to the mount (3). The fastening elements (12) bridge an interstice (11) between the optical element (2) and the mount (3), and a purge device (15) produces at least one purge gas flow (16) in the region of the optical element (2) such that the purge gas flow flows around the fastening areas (14) of the fastening elements (12).Type: GrantFiled: October 12, 2016Date of Patent: December 4, 2018Assignee: CARL ZEISS SMT GMBHInventors: Michael Brehm, Wolfgang Merkel, Ulrich Weber, Henry Wegert
-
Patent number: 10021861Abstract: Described herein are immunodeficient non-human animals lacking expression of toll-like receptor 4 (TLR4) by endogenous autogeneic innate immune cells, as well as methods and compositions for engraftment of xenogeneic hematopoietic stem cells in the immunodeficient non-human animal lacking expression of toll-like receptor 4 (TLR4), thereby creating an innate immune system in the animal derived from the xenogeneic hematopoietic stem cells. Further described are immunodeficient mice lacking expression of toll-like receptor 4 by endogenous autogeneic innate immune cells, as well as methods and compositions for engraftment of xenogeneic hematopoietic stem cells in the immunodeficient mouse lacking expression of toll-like receptor 4, thereby creating an innate immune system in the animal derived from the xenogeneic hematopoietic stem cells.Type: GrantFiled: August 15, 2016Date of Patent: July 17, 2018Assignees: The Jackson Laboratory, University of MassachusettsInventors: Leonard D. Shultz, Dale L. Greiner, Michael A. Brehm
-
Publication number: 20180184629Abstract: The present invention relates generally to genetically modified non-human animals and immunodeficient non-human animals characterized by restored complement-dependent cytotoxicity, as well as methods and compositions for assessment of therapeutic antibodies in the genetically modified immunodeficient non-human animals. In specific aspects, the present invention relates to immunodeficient non-obese diabetic (NOD), A/J, A/He, AKR, DBA/2, NZB/BIN, B10.D2/oSn and other mouse strains genetically modified to restore complement-dependent cytotoxicity which is lacking in the unmodified immunodeficient mice. In further specific aspects, the present invention relates to NOD.Cg-Prkdcscid IL2rgtm1Wj1/SzJ (NSG), NOD. Cg-Rag1tm1Mom IL2rgtm1Wj1/SzJ (NRG) and NOD.Cg-Prkdcscid IL2rgtm1Wj1/JicTAc (NOG) mice genetically modified to restore complement-dependent cytotoxicity which is lacking in unmodified NSG, NRG and NOG mice.Type: ApplicationFiled: June 16, 2016Publication date: July 5, 2018Inventors: Leonard D. Shultz, Mohit Kumar Verma, Dale L. Greiner, Michael A. Brehm
-
Publication number: 20170102539Abstract: An optical assembly (1) includes an optical element (2), a mount (3) configured to hold the optical element (2), and a plurality of fastening elements (12) with fastening areas (14) configured to fasten the optical element (2) to the mount (3). The fastening elements (12) bridge an interstice (11) between the optical element (2) and the mount (3), and a purge device (15) produces at least one purge gas flow (16) in the region of the optical element (2) such that the purge gas flow flows around the fastening areas (14) of the fastening elements (12).Type: ApplicationFiled: October 12, 2016Publication date: April 13, 2017Inventors: Michael BREHM, Wolfgang MERKEL, Ulrich WEBER, Henry WEGERT
-
Publication number: 20160345548Abstract: Described herein are immunodeficient non-human animals lacking expression of toll-like receptor 4 (TLR4) by endogenous autogeneic innate immune cells, as well as methods and compositions for engraftment of xenogeneic hematopoietic stem cells in the immunodeficient non-human animal lacking expression of toll-like receptor 4 (TLR4), thereby creating an innate immune system in the animal derived from the xenogeneic hematopoietic stem cells. Further described are immunodeficient mice lacking expression of toll-like receptor 4 by endogenous autogeneic innate immune cells, as well as methods and compositions for engraftment of xenogeneic hematopoietic stem cells in the immunodeficient mouse lacking expression of toll-like receptor 4, thereby creating an innate immune system in the animal derived from the xenogeneic hematopoietic stem cells.Type: ApplicationFiled: August 15, 2016Publication date: December 1, 2016Inventors: Leonard D. Shultz, Dale L. Greiner, Michael A. Brehm
-
Patent number: 9414576Abstract: Described herein are immunodeficient non-human animals lacking expression of toll-like receptor 4 (TLR4) by endogenous autogeneic innate immune cells, as well as methods and compositions for engraftment of xenogeneic hematopoietic stem cells in the immunodeficient non-human animal lacking expression of toll-like receptor 4 (TLR4), thereby creating an innate immune system in the animal derived from the xenogeneic hematopoietic stem cells. Further described are immunodeficient mice lacking expression of toll-like receptor 4 by endogenous autogeneic innate immune cells, as well as methods and compositions for engraftment of xenogeneic hematopoietic stem cells in the immunodeficient mouse lacking expression of toll-like receptor 4, thereby creating an innate immune system in the animal derived from the xenogeneic hematopoietic stem cells.Type: GrantFiled: October 10, 2014Date of Patent: August 16, 2016Assignees: The Jackson Laboratory, University of MassachusettsInventors: Leonard D. Shultz, Dale L. Greiner, Michael A. Brehm
-
Publication number: 20150105288Abstract: Described herein are immunodeficient non-human animals lacking expression of toll-like receptor 4 (TLR4) by endogenous autogeneic innate immune cells, as well as methods and compositions for engraftment of xenogeneic hematopoietic stem cells in the immunodeficient non-human animal lacking expression of toll-like receptor 4 (TLR4), thereby creating an innate immune system in the animal derived from the xenogeneic hematopoietic stem cells. Further described are immunodeficient mice lacking expression of toll-like receptor 4 by endogenous autogeneic innate immune cells, as well as methods and compositions for engraftment of xenogeneic hematopoietic stem cells in the immunodeficient mouse lacking expression of toll-like receptor 4, thereby creating an innate immune system in the animal derived from the xenogeneic hematopoietic stem cells.Type: ApplicationFiled: October 10, 2014Publication date: April 16, 2015Inventors: Leonard D. Shultz, Dale L. Greiner, Michael A. Brehm
-
Patent number: 8203784Abstract: The invention is directed to a multispectral illumination device for a microscope or for a reader. According to the invention, the illumination device comprises at least three receptacle positions for lighting modules and at least one receptacle position for coupling modules, the mechanical devices for connecting the lighting modules or coupling modules at the receptacle positions to the illumination device being designed in such a way that the lighting modules or coupling modules can be easily changed. Further, the receptacle positions are arranged in such a way that, with suitable selection of the lighting modules and coupling modules, all individual spectra of the lighting modules in a total spectrum are available simultaneously at the output of the illumination device.Type: GrantFiled: October 6, 2007Date of Patent: June 19, 2012Assignee: Carl Zeiss MicroImaging GmbHInventors: Andreas Nolte, Matthias Kramer, Michael Brehm, Christian Boeker